SIGY · Sigyn Therapeutics, Inc. · Webcasts, Transcripts & Audio
$0.03
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“The Company had an accumulated deficit of $17,379,978 at September 30, 2025, had a working capital deficit of $3,903,920 at September 30, 2025, had net losses of $578,503 and $2,698,254, and $1,196,923 and $2,817,394 for the three and nine months ended September 30, 2025 and 2024, respectively, and net cash used in operating activities of $646,208 and $582,218 for the nine months ended September 30, 2025 and 2024, respectively, with no revenue earned since inception, and a lack of operational history. These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$44,951
Shares
1.61M
Volume · Nov 6
2000
Avg daily vol (3M)
22.72K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Sigyn Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Sigyn Therapeutics, Inc. (SIGY), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.